Skip to main content

Drug Interactions between azathioprine and moexipril

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

azaTHIOprine moexipril

Applies to: azathioprine and moexipril

MONITOR: Limited clinical data suggest that angiotension converting enzyme (ACE) inhibitors and azathioprine may have additive hematologic effects, resulting in an increased risk of neutropenia or leukopenia during coadministration. Data have been reported for captopril and enalapril. It is unknown whether this effect could occur with other ACE inhibitors.

MANAGEMENT: Patients should be monitored for clinical and laboratory evidence of hematologic abnormalities during concomitant administration. Patients should be advised to report symptoms such as unusual bleeding, bruising, fever, sore throat, mouth sores, or symptoms of infection.

References (7)
  1. Edwards CR, Drury P, Penketh A, Damluji SA (1981) "Successful reintroduction of captopril following neutropenia." Lancet, 1, p. 723
  2. Elijovisch F, Krakoff LR (1980) "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet, 1, p. 927-8
  3. Gossmann J, Thurmann P, Bachmann T, Weller S, Kachel HG, Schoeppe W, Scheuermann EH (1996) "Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients." Kidney Int, 50, p. 973-8
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  5. Cerner Multum, Inc. "Australian Product Information."
  6. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  7. (2014) "Product Information. Azasan (azathioprine)." Salix Pharmaceuticals

Drug and food interactions

Moderate

moexipril food

Applies to: moexipril

GENERALLY AVOID: Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors. In some cases, affected patients were using a potassium-rich salt substitute. ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.

MANAGEMENT: It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake. Particular attention should be paid to the potassium content of salt substitutes.

References (3)
  1. (2002) "Product Information. Vasotec (enalapril)." Merck & Co., Inc
  2. Good CB, McDermott L (1995) "Diet and serum potassium in patients on ACE inhibitors." JAMA, 274, p. 538
  3. Ray K, Dorman S, Watson R (1999) "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens, 13, p. 717-20

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer